PETALING JAYA: Duopharma Biotech Bhd
aims to deliver a satisfactory performance in 2025, barring unforeseen market changes and developments.
In a filing with Bursa Malaysia, Duopharma said this would be achievable with a resolute focus on sustainable growth, cost optimisation and operational resilience.
For the fourth quarter ended Dec 31, 2024, Duopharma’s net profit rose to RM15.08mil from RM8.5mil in the previous corresponding period, while revenue grew to RM193.67mil from RM167.50mil a year earlier.
For the financial year ended Dec 31, 2024, Duopharma’s net profit rose to RM62.65mil from RM52.65mil a year earlier, while revenue improved to RM813.70mil from RM704.73mil previously.
